Поиск по репозиторию
Статья
Enisamium Reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity
2021
Infections with respiratory viruses constitute a huge burden on our health and economy. Antivirals against some respiratory viruses are available, but further options are urgently needed. Enisamium iodide (laboratory code FAV00A, trade name Amizon) is an antiviral, marketed in countries of the Commonwealth of Independent States for the treatment of viral respiratory infections, but its clinical efficacy and mode of action are not well understood. In this study, we investigated the efficacy of enisamium in patients aged between 18 and 60 years with confirmed influenza virus and other viral respiratory infections. Enisamium treatment resulted in reduced influenza virus shedding (at day 3, 71.2% in the enisamium group tested negative versus 25.0% in placebo group [P
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-01
Метаданные
Название журнала
- Antimicrobial Agents and Chemotherapy
Том
- 65
Выпуск
- 4
Финансирующая организация
- National Institutes of Health
Номер гранта
- R21AI147172
Тип документа
- journal article
Тип лицензии Creative Commons
- CC BY
Правовой статус документа
- Свободная лицензия
Источник
- scopus
